Biogen (BIIB) Stock Forecast & Price Target

Q: What analysts cover Biogen?

Biogen has been rated by research analysts at Argus , Bank of America , Barclays , BMO Capital Markets , Canaccord Genuity Group , Citigroup , Guggenheim , HC Wainwright , HSBC , JPMorgan Chase & Co. , Morgan Stanley , Needham & Company LLC , Piper Sandler , Robert W. Baird , Royal Bank Of Canada , Stifel Nicolaus , TD Cowen , Truist Financial , UBS Group , Wedbush , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$251.48 -1.92 (-0.76%)

As of 03:27 PM Eastern

Compare

Biogen - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 33 Analyst Ratings

Sell
1

Hold
10

Buy
22

Based on 33 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 33 analysts, 1 has given a sell rating, 10 have given a hold rating, 21 have given a buy rating, and 1 has given a strong buy rating for BIIB.

Consensus Price Target

$254.41
1.17% Upside

According to the 33 analysts' twelve-month price targets for Biogen, the average price target is $254.41. The highest price target for BIIB is $310.00, while the lowest price target for BIIB is $175.00. The average price target represents a forecasted upside of 1.17% from the current price of $251.48.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIIB Analyst Ratings Over Time

Type	Current Forecast 11/12/25 to 11/12/26	1 Month Ago 10/13/25 to 10/13/26	3 Months Ago 8/14/25 to 8/14/26	1 Year Ago 11/12/24 to 11/12/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	21 Buy rating(s)	18 Buy rating(s)	18 Buy rating(s)	10 Buy rating(s)
Hold	10 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)	15 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$254.41	$236.04	$227.07	$177.44
Forecasted Upside	1.17% Upside	3.12% Upside	8.22% Upside	9.84% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Healthcare Companies	Broader Market
Consensus Rating Score	2.67	2.32	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	0.85% Upside	111.41% Upside	13.70% Upside
News Sentiment Rating	Positive News See Recent BIIB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
11/9/2026	Piper Sandler 2 of 5 stars	David Amsellem 5 of 5 stars	Reiterated Rating	Overweight	$245.00 ➝ $305.00	+19.54%
11/2/2026	Guggenheim 5 of 5 stars	Brad Canino 5 of 5 stars	Boost Target	Buy	$280.00 ➝ $300.00	+18.29%
11/2/2026	HC Wainwright 4 of 5 stars	Ananda Ghosh 3 of 5 stars	Boost Target	Buy	$251.00 ➝ $270.00	+6.46%
10/29/2026	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Hold (C) ➝ Hold (C-)
10/29/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Brian Abrahams Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$256.00 ➝ $272.00	+8.11%
10/29/2026	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Laura Chico Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$212.00 ➝ $225.00	-7.81%
10/29/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Yee Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$270.00 ➝ $300.00	+19.24%
10/29/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Sumant Kulkarni Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$248.00 ➝ $272.00	+8.95%
10/29/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Matthew Harrison Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Equal Weight	$231.00 ➝ $238.00	-5.09%
10/29/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Phil Nadeau Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$250.00 ➝ $260.00	+3.26%
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
10/29/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Danielle Brill Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$235.00 ➝ $260.00	+3.35%
10/29/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Jasper Hellweg Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Hold ➝ Buy	$280.00	+14.73%
10/29/2026	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Ami Fadia Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$256.00 ➝ $290.00	+18.83%
10/29/2026	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Brian Skorney Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$250.00 ➝ $290.00	+18.83%
10/28/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Geoff Meacham Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Neutral
10/28/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Emily Field Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Equal Weight	$200.00 ➝ $230.00	-8.31%
10/22/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Jason Zemansky Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$219.00 ➝ $244.00	+1.25%
10/20/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Mohit Bansal Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$250.00 ➝ $310.00	+29.17%
10/12/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Market Perform	$220.00	-5.12%
10/12/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Chris Schott Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Neutral ➝ Overweight	$210.00 ➝ $300.00	+32.91%
9/10/2026	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Paul Matteis Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$242.00	+12.68%
9/10/2026	HSBC Subscribe to MarketBeat All Access to unlock brokerage rankings	Morten Herholdt Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Reduce	$165.00 ➝ $175.00	-16.96%
8/13/2026	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Alexandria Hammond Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Peer Perform ➝ Outperform	$300.00	+43.63%
8/4/2026	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Salim Syed Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$221.00 ➝ $241.00	+16.11%
7/29/2026	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Jay Olson Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform	$300.00	+43.24%
7/28/2026	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Strong Sell ➝ Hold
7/13/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Buy
6/22/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Overweight
5/15/2026	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings		Initiated Coverage	Outperform
5/1/2026	Freedom Capital Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold ➝ Strong-Buy
4/30/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target		$180.00 ➝ $190.00	+0.57%
4/30/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target		$201.00 ➝ $200.00	+5.87%
4/24/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Buy	$231.00 ➝ $238.00	+29.08%
2/9/2026	Tudor Pickering Subscribe to MarketBeat All Access to unlock brokerage rankings	William Pickering Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$201.00	-0.09%
9/24/2025	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform
2/13/2025	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	George Farmer Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Sector Outperform	$244.00 ➝ $224.00	+61.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:27 PM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 11, 2026. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

Biogen Inc. recently reported strong third-quarter financial results, beating analyst expectations with an earnings per share of $2.62 compared to the consensus estimate of $1.99, while also generating revenue of $2.80 billion, which exceeded the projected $2.63 billion and represented a 10.6% year-over-year increase.
The stock is currently trading at $253.40, which is near its 52-week high of $261.00, indicating strong recent momentum and a significant recovery from its 52-week low of $158.05, suggesting that the market is increasingly confident in the company's trajectory.
Biogen Inc. has received a "Moderate Buy" consensus rating from sell-side analysts, with an average price target of $252.34, reflecting a positive outlook that is supported by recent upgrades from firms such as Wolfe Research and Wells Fargo, which raised their price targets to $300.00 and $310.00 respectively.
Institutional investors have shown significant confidence in the company, with major funds such as the Illinois Municipal Retirement Fund and Retirement Systems of Alabama substantially increasing their holdings in the third quarter, with the latter raising its position by 1,697.5% to own approximately 557,499 shares.
The company is advancing its pipeline with positive clinical data, including the presentation of Phase 3 results for dapirolizumab pegol in systemic lupus erythematosus at the ACR 2026 conference, which indicated greater treatment response rates compared to placebo, potentially opening new therapeutic markets.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

Biogen Inc. does not currently pay a dividend, as indicated by a dividend yield of 0.00%, which may be a drawback for income-focused investors seeking regular cash flow from their biotechnology holdings.
The company's earnings per share has declined significantly year-over-year, dropping from $4.81 in the same quarter last year to $2.62 in the most recent quarter, suggesting potential challenges in maintaining profitability or managing costs despite revenue growth.
Short interest in the stock has been relatively high, with approximately 5.45 million shares shorted as of the most recent record date, representing about 3.7% of the float, which indicates that a notable portion of the market is betting against the stock's performance.
Some analysts remain cautious about the valuation, with BMO Capital Markets maintaining a "market perform" rating and a price target of $220.00, which is below the current stock price of $253.40, suggesting that the stock may be overvalued relative to its fundamental earnings power.
The company's beta of 0.10, while indicating low volatility relative to the market, may also suggest that the stock is less responsive to broader market rallies, potentially limiting upside potential during periods of strong overall market growth.

BIIB Forecast - Frequently Asked Questions

According to the research reports of 33 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $254.41, with a high forecast of $310.00 and a low forecast of $175.00.

33 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There is currently 1 sell rating, 10 hold ratings, 21 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.

According to analysts, Biogen's stock has a predicted upside of 1.17% based on their 12-month stock forecasts.

Over the previous 90 days, Biogen's stock had 3 upgrades and 1 downgrade by analysts.

Biogen has been rated by research analysts at Argus, Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Guggenheim, HC Wainwright, HSBC, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Biogen more than other "healthcare" companies. The consensus rating for Biogen is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Biogen Recommendations

MarketBeat monitors more than a dozen sources for Biogen analyst ratings, with the most recent rating issued on 11/9/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target